Ophirex, Inc.

About Ophirex, Inc.

Ophirex is pioneering a new approach to treating snakebite, aiming to revolutionize a field that has seen little change in over 100 years. Their mission is to reduce the time to treatment from hours to minutes through innovative solutions.

Products & Services

Varespladib for Human Use:A small-molecule inhibitor of snake venom secretory phospholipase A2 (sPLA2), designed as an oral treatment for snakebite in humans.

Varespladib for Animal Use:A treatment targeting snakebite in animals, based on the same small-molecule inhibitor technology as the human version.

Specialties

Snakebite treatment Small-molecule inhibitors Secretory phospholipase A2 (sPLA2) inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 37000000 MR: - FA: $37 million FAN: 37000000	D: 2023-01-05 FD: 2023-01-05	1 investors

Series B Latest

2023-01-05

$37.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rebecca Carter

Chief Operating Officer

M

Matthew R. Lewin

Founder and Board Member

J

Jerry Harrison

Director

J

Jeremy Gowler

Chief Executive Officer

T

Timothy Platts-Mills

Chief Medical Officer

L

Leslie Boyer

Chief Scientific Officer

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Ophirex, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised